Showing 2,841 - 2,860 results of 5,570 for search '"Oncology"', query time: 0.07s Refine Results
  1. 2841
  2. 2842
  3. 2843
  4. 2844
  5. 2845
  6. 2846
  7. 2847
  8. 2848
  9. 2849
  10. 2850

    Serum Pharmacochemistry and Network Pharmacology Reveal Active Compounds and Mechanisms of the Huaxian Formula in Alleviating Radiation-Induced Pulmonary Fibrosis by Gong C, Chen J, Zou P, Fang Z, Quan L, Wang J, Yin J, Lin B, Lang J, Chen M

    Published 2025-01-01
    “…CuiCui Gong,1– 3 Junyang Chen,2 Pingjin Zou,2 Zengyi Fang,2 Li Quan,1– 3 Jing Wang,2,4 Jie Yin,2,5 Bing Lin,1 Jinyi Lang,1– 5 Meihua Chen2,3 1School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610032, People’s Republic of China; 2Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610041, People’s Republic of China; 3Institute of Integrated Traditional Chinese and Western Medicine Cancer Research, Chengdu University of Traditional Chinese Medicine, Chengdu, 610032, People’s Republic of China; 4Department of Oncology, School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China; 5School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 611731, People’s Republic of ChinaCorrespondence: Jinyi Lang, School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 610032, People’s Republic of China, Email langjy610@163.com Meihua Chen, Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610041, People’s Republic of China, Email chenmeihua@scszlyy.org.cnPurpose: Radiation-induced pulmonary fibrosis (RIPF) is a serious complication of radiotherapy that lacks effective treatment options. …”
    Get full text
    Article
  11. 2851
  12. 2852
  13. 2853
  14. 2854
  15. 2855
  16. 2856
  17. 2857
  18. 2858
  19. 2859

    Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer by Lei Wang, Yafei You, Wenzhuo He, Yu Hou, Lan Li, Li Wang, Chang Jiang, Jiahong Yi, Yaoxiong Xia, Liangping Xia

    Published 2025-01-01
    “…Patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 2 had worse median PFS comparing with those with ECOG PS score of 0–1 (3.8 vs. 12.6 months, P = 0.004). …”
    Get full text
    Article
  20. 2860